黄芪与当归在肾脏微血管病变中的治疗应用前景  

Therapeutic Application and Prospect of Astragalus membranaceus and Angelica sinensis in Treating Renal Mierovascular Lesions

作　　者：宋锦叶[1] 孟立强[1] 李晓玫[1] 

机构地区：[1]北京大学第一医院肾内科,北京大学肾脏病研究所,卫生部肾脏疾病重点实验室,北京100034

出　　处：《中国中西医结合杂志》2008年第9期859-861,共3页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：国家自然科学基金重点项目(No.30330710)

摘　　要：肾脏组织局部微血管病变促进了肾小球硬化和间质纤维化的进展。现代药理学研究表明中药黄芪与当归能够通过多种途径改善微血管病变,包括增加局部组织的血流灌注以减轻组织的缺氧性损伤、促进缺血再灌注后肾血流量和肾小球滤过率的恢复、纠正一氧化氮/血管紧张素等血管活性物质的失衡、抑制细胞内钙的释放和促进血管表皮生长因子表达及血管内皮细胞DNA合成以改善内皮细胞功能。提示黄芪、当归可能通过上述机制起到延缓肾脏疾病进展作用。It has been known that the renal microvasular lesions could aggravate the progress of glomerular sclerosis and tubulo-interstitial fibrosis in chronic kidney diseases. Modern pharmacological studies indicated that the two traditional Chinese herbs, Astragalus membranaceus and Angelica sinensis, could improve micorvascular le- sions through muhiple mechanisms, including increasing local renal blood flow to lessen the hypoxic renal injury, promoting the recovery of renal blood flow and glomerular filtration rate after ischemia-reperfusion, modulating the imbalance of vaso-activators such as nitric oxide and angiotensin, increasing the expression of vascular epithelial growth factor and inhibiting the release of the intracellular calcium ion and promoting DNA synthesis in endothelial cells to improve the function of endothelial cells. These evidences suggest that Astragalus membranaceus and Angelica sinensis may retard the progress of renal diseases through the above-mentioned mechanisms.

关 键 词：黄芪 当归 微血管病变 

分 类 号：R277.5[医药卫生—中医学]